Nature's Sunshine Products (NATR) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nature's Sunshine Products (NATR) has outperformed Sionna Therapeutics (SION) over the past year, losing 16.2% versus a loss of 82.8%. Sionna Therapeutics is the larger company by market cap ($221.2 million vs $221.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NATR | SION |
|---|---|---|
| Share price | $12.57 | $4.90 |
| Market cap | $221.18M | $221.24M |
| 1-day change | -0.16% | +1.66% |
| YTD return | -41.75% | -88.09% |
| 1-year return | -16.20% | -82.81% |
| 5-year return | -18.09% | — |
| P/E ratio (TTM) | 12.45 | — |
| Forward P/E | 10.22 | — |
| EPS (TTM) | $1.01 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.14 | $54.97 |
| 52-week low | $12.31 | $4.01 |
| Distance from 52-week high | -55.33% | -91.09% |
| Analyst consensus | none | hold |
| Avg. price target upside | +142.64% | +328.57% |
| Average volume | 160.23K | 2.19M |
| Shares outstanding | 17.60M | 45.15M |
| Employees | 806 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NATR has outperformed SION by 66.6 percentage points over the past year.
About Nature's Sunshine Products
NATR stock →Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.
Health Care · Biotechnology: Pharmaceutical Preparations · 806 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
NATR vs SION FAQ
Which is bigger, Nature's Sunshine Products or Sionna Therapeutics?
Sionna Therapeutics (SION) is larger, with a market capitalization of $221.24M compared with $221.18M for Nature's Sunshine Products (NATR).
Which stock has performed better over the past year, NATR or SION?
NATR returned -16.20% over the past 12 months, compared with -82.81% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Nature's Sunshine Products and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.